Company news

Actuate Therapeutics, Inc. news in 2026

Actuate Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026

November 18, 2026

Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026

November 4, 2026

Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets

November 2, 2026

Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering

October 27, 2026

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

June 8, 2026

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

May 31, 2026

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

May 10, 2026

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

May 6, 2026

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

April 13, 2026

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

March 8, 2026

Actuate Therapeutics to Present at The Citizens Life Sciences Conference

March 4, 2026

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 24, 2026

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

January 21, 2026

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

January 12, 2026

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO...

January 11, 2026

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

January 6, 2026

Decks in 2026